Abstract Details

Title Treatment of Cerebral Radiation Necrosis with Bevacizumab: The Cleveland Clinic Experience

Topic Neuro-oncology

Presentation(s) S56 - (-)

Poster/Presentation
Number 005

Objective

Background Cerebral radiation necrosis is a devastating complication of radiation therapy of brain tumors. Recent studies have explored the role of bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor in the treatment of radiation necrosis of the brain. We report twenty patients with cerebral radiation necrosis who were treated with bevacizumab.

Design/Methods Twenty patients diagnosed with cerebral radiation necrosis and treated with bevacizumab between July 2007 and January 2011 were identified from the Cleveland Clinic Brain Tumor and Neuro-Oncology Center's database. Pre- and post-treatment magnetic resonance imaging (MRI) studies were compared to evaluate bevacizumab efficacy.

Results Post-treatment MRI demonstrated a radiographic response in all patients on the fluid-attenuated inversion-recovery (FLAIR) sequences and 19 of 20 patients showed improvement in the T1-weighted post-Gadolinium contrast images. The average area change in the T1-weighted post-Gadolinium contrast abnormalities was a decrease of 50.3%, and the average change in the FLAIR images was a decrease of 51.8% (using McDonald criteria). There was a mean daily dose reduction of 9.6 mg of dexamethasone after initiation of bevacizumab in patients who were on steroids at the start of bevaciuzmab therapy for radiation necrosis.

Conclusions Bevacizumab reduced cerebral edema in radiographic imaging and demonstrated a clinical benefit in patients with cerebral radiation necrosis. Bevacizumab may be onsidered as a therapeutic option in cases that do not respond to traditional corticosteroid therapy.

Authors/Disclosures
Glen H. Stevens, DO, PhD, FAAN (Cleveland Clinic Foundation) PRESENTER	The institution of Dr. Stevens has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Stevens has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for EBSCO. The institution of Dr. Stevens has received research support from National Cancer Institute.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Steven S. Rosenfeld, MD, PhD (The Neurological Institute of New York)	No disclosure on file
Bruce S. Rubin, MD, FAAN (Design Neuroscience Center)	No disclosure on file
Jeremy N. Rich, MD (University of Pittsburgh)	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��